- |||||||||| Clinical data, Enrollment change, Trial termination, Trial primary completion date: NP01: Photon/Proton Radiation Therapy for Carcinoma of the Nasopharynx (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=9, Terminated, Completed --> Active, not recruiting N=174 --> 9 | Recruiting --> Terminated | Trial primary completion date: Oct 2056 --> Jul 2015; Slow enrollment, Feasibility issues
- |||||||||| OPB-51602 / Otsuka
Biomarker, Enrollment change, Trial termination, Trial primary completion date, Metastases: OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy (clinicaltrials.gov) - Jun 20, 2015 P1, N=9, Terminated, Recruiting --> Completed | N=200 --> 75 N=45 --> 9 | Recruiting --> Terminated | Trial primary completion date: Oct 2015 --> May 2015; Lactic and metabolic acidosis of OPB-51602 is not tolerable
- |||||||||| Aqupla (nedaplatin) / Simcere
Enrollment change, Trial termination, Trial primary completion date: NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation (clinicaltrials.gov) - Jun 15, 2015 P2, N=10, Terminated, N=45 --> 9 | Recruiting --> Terminated | Trial primary completion date: Oct 2015 --> May 2015; Lactic and metabolic acidosis of OPB-51602 is not tolerable N=66 --> 10 | Recruiting --> Terminated | Trial primary completion date: Sep 2014 --> Sep 2015; slow patient enrollment
- |||||||||| Epstein-Barr Virus Specific Immunotherapy - Dana / Farber Cancer Institute
Trial primary completion date: Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov) - Jun 11, 2015 P=N/A, N=10, Active, not recruiting, Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Feb 2014 --> Jan 2016
- |||||||||| cisplatin / Generic mfg., docetaxel / Generic mfg., sorafenib / Generic mfg.
Enrollment closed, Combination therapy, Metastases: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Apr 14, 2015 P1/2, N=41, Active, not recruiting, Trial primary completion date: May 2013 --> Dec 2016 Suspended --> Active, not recruiting
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, motolimod (VTX 2337) / BMS
Trial completion, Combination therapy, Metastases: TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck (clinicaltrials.gov) - Mar 7, 2015 P1, N=13, Completed, Recruiting --> Completed | N=18 --> 22 | Trial primary completion date: May 2016 --> Mar 2015 Active, not recruiting --> Completed
- |||||||||| Inlyta (axitinib) / Pfizer
Trial primary completion date, Metastases: Nasopharyngeal Carcinoma (NPC) Axitinib (clinicaltrials.gov) - Dec 12, 2014 P2, N=37, Recruiting, Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Dec 2014 --> Jun 2015
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, motolimod (VTX 2337) / BMS
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck (clinicaltrials.gov) - Nov 11, 2014 P1, N=13, Active, not recruiting, Recruiting --> Completed | N=52 --> 18 | Trial primary completion date: Dec 2010 --> May 2011 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2014
- |||||||||| Enrollment change, Trial termination, Trial primary completion date, Surgery: Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer (clinicaltrials.gov) - Nov 10, 2014
P=N/A, N=7, Terminated, Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2014 N=30 --> 7 | Recruiting --> Terminated | Trial primary completion date: Mar 2017 --> Nov 2014; The study will be rewritten as a data registry study
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Phase classification, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Sep 28, 2014 P1, N=43, Active, not recruiting, Terminated --> Completed Phase classification: P1/2 --> P1
- |||||||||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment change, Trial termination, Trial primary completion date: SOX as Salvage Treatment in Nasopharyngeal Carcinoma (clinicaltrials.gov) - Aug 21, 2014 P2, N=16, Terminated, Completed --> Terminated; Due to a lack of funding N=48 --> 16 | Recruiting --> Terminated | Trial primary completion date: Jul 2013 --> Dec 2014; poor accrual of eligible patients
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Combination therapy, Metastases: Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 12, 2014 P1/2, N=66, Completed, Phase classification: P1/2 --> P1 Trial primary completion date: Jul 2008 --> Oct 2007
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 9, 2014 P1/2, N=66, Completed, Trial primary completion date: Jul 2008 --> Oct 2007 Recruiting --> Completed
- |||||||||| MK-2206 / Merck (MSD)
Trial primary completion date, Metastases: MK-2206 in Recurrent Nasopharyngeal Carcinoma (clinicaltrials.gov) - May 20, 2014 P2, N=45, Active, not recruiting, Active, not recruiting --> Completed Trial primary completion date: May 2014 --> May 2015
- |||||||||| MK-2206 / Merck (MSD)
Trial completion date, Metastases: MK-2206 in Recurrent Nasopharyngeal Carcinoma (clinicaltrials.gov) - May 20, 2014 P2, N=45, Active, not recruiting, Trial primary completion date: May 2014 --> May 2015 Trial completion date: May 2014 --> May 2015
- |||||||||| cisplatin / Generic mfg., docetaxel / Generic mfg., sorafenib / Generic mfg.
Trial initiation date, Combination therapy, Metastases: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - May 11, 2014 P1/2, N=41, Recruiting, Trial completion date: May 2014 --> May 2014 Initiation date: Jan 2014 --> Apr 2014
|